Skip to main content

Table 1 Up-regulated genes in BMDCs treated with SLC for 1 or 12 hours

From: Combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinoma

Unigene

Genebank

Description

Gene name

Exp.1

Exp.2

Exp.2/Exp.1

Ca 2+ pathway

      

Mm.3064

NM_007922

M.musculus mRNA for elk1 protein

Elk-1

1.509E-01

3.941E-01

2.612E + 00

Mm.195050

NM_007923

ELK4, member of ETS oncogene family

Sap 1a

2.183E-02

1.673E-01

7.662E + 00

PKC pathway

      

Mm.896

NM_008362

Interleukin 1 receptor, type I

IL-1R1

1.194E-04

9.819E-04

8.223E + 00

Protein tyrosine kinase pathway

      

Mm.22288

NM_007631

Cyclin D1

Cyclin D1

2.426E-02

3.758E-01

1.549E + 01

Mm.16110

NM_007633

Cyclin E1

Ccnel

4.159E-02

2.403E-01

5.778E + 00

Mm.35867

NM_009830

Cyclin E2

Cyclin E2

2.048E-01

4.335E-01

2.117E + 00

NF- κB pathway

      

Mm.76649

NM_011693

Vascular cell adhesion molecule 1

VCAM-1

9.880E-02

2.347E-01

2.376E + 00

JAK-STAT pathway

      

Mm.34446

NM_007669

Cyclin-dependent kinase inhibitor 1A (P21)

p21Waf1/p21cip

8.938E-03

7.725E-02

8.642E + 00

  1. Exp.1 represented the expression of the genes in BMDCs treated with SLC for 1 hour; Exp.2 represented the expression of genes in BMDCs treated with SLC for 12 hours; Exp.2/Exp.1 meant the fold change.